Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewJF-NP-26
Description: Caged Raseglurant (Cat. No. 4416)
Chemical Name: (7-(Diethylamino)-2-oxo-2H-chromen-4-yl)methyl (2-((3-fluorophenyl)ethynyl)-4,6-dimethylpyridin-3-yl)carbamate
Purity: ≥98% (HPLC)
Biological Activity for JF-NP-26
JF-NP-26 is a caged Raseglurant (Cat. No. 4416). Releases raseglurant upon exposure to 405 nm (violet) light. Inhibits the effects of Quisqualate (Cat. No. 0188) in cultured neurons when exposed to 405 nm light. Exhibits analgesic activity in pain models in vivo on photoactivation. Quantum yield = 0.18.
Technical Data for JF-NP-26
| M. Wt | 513.56 |
| Formula | C30H28FN3O4 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 2341841-03-8 |
| Smiles | CC1=CC(C)=C(NC(OCC2=CC(OC3=C2C=CC(N(CC)CC)=C3)=O)=O)C(C#CC4=CC=CC(F)=C4)=N1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for JF-NP-26
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 51.36 | 100 |
Preparing Stock Solutions for JF-NP-26
The following data is based on the product molecular weight 513.56. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.95 mL | 9.74 mL | 19.47 mL |
| 5 mM | 0.39 mL | 1.95 mL | 3.89 mL |
| 10 mM | 0.19 mL | 0.97 mL | 1.95 mL |
| 50 mM | 0.04 mL | 0.19 mL | 0.39 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for JF-NP-26
References for JF-NP-26
References are publications that support the biological activity of the product.
Font et al (2017) Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator. eLIFE 6 e23545 PMID: 28395733
If you know of a relevant reference for JF-NP-26, please let us know.
View Related Products by Target
Keywords: JF-NP-26, JF-NP-26 supplier, caged-raseglurant, ADX, 10059, photoactivation, photolysis, violet, light, mGlu5, receptors, NAM, negative, allosteric, modulator, Caged, Glutamate, Compounds, 6553, Tocris Bioscience
Citations for JF-NP-26
Citations are publications that use Tocris products.
Currently there are no citations for JF-NP-26. Do you know of a great paper that uses JF-NP-26 from Tocris? Please let us know.
Reviews for JF-NP-26
There are currently no reviews for this product. Be the first to review JF-NP-26 and earn rewards!
Have you used JF-NP-26?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.